This report presents the findings from the evaluation of Gavi’s 2013 Gender Policy. The evaluation was conducted by Itad in 2018-2019.

This report presents the main findings of the evaluation of Gavi supported measles supplementary immunisation activities in Nigeria.

This report presents the main findings from an evaluation of Gavi’s support to civil society organisations (CSOs) during the period 2011 to 2017. The evaluation was conducted by Itad in 2018.

This evaluation covers the implementation of the eighth Memorandum of Understanding (MOU8; 2016-2020) between Gavi, the Vaccine Alliance, and UNICEF Supply Division (SD).

Evaluations of health system strengthening (HSS) grants help countries and Gavi to continuously learn and improve the support.

Gavi’s health system strengthening (HSS) support is regularly evaluated to provide valuable insights into the HSS programme.

The 2009 review of Gavi's health system strengthening support includes 21 country case studies.

The 2008 HSS tracking study is complementary to the HSS evaluation, providing a more in depth country perspective that helped highlight implementation issues in 6 countries.

Gavi, the Vaccine Alliance launched a prospective evaluation to collect real-time data on immunisation programmes, vaccine-related issues and the contribution of Alliance support in four countries.

An evaluation is currently under way to assess the relevance, effectiveness and efficiency of technical assistance to countries through Gavi’s partners’ engagement framework (PEF).

This report presents the main findings from an evaluation of Gavi’s support to Albania and its transition after funding ended. The evaluation was conducted by the Curatio International Foundation in 2015.

This report presents the lessons learnt and recommendations from an evaluation of Gavi’s support to Bosnia and Herzegovina and its transition after funding ended. The evaluation was conducted by the Curatio International Foundation in 2014.

This report presents the lessons learnt and recommendations from an independent evaluation of the Gavi co-financing policy conducted by the Norwegian Institute of Public Health in 2014.

This report presents the findings and lessons from an evaluation of the Gavi-Government of China Hepatitis B vaccination programme. The evaluation was conducted in 2012 by Abt Associates.

This report presents the findings and lessons from an evaluation of the Gavi Gender Policy. The evaluation was conducted in 2012 by ICF Macro, Inc.

This report presents the findings of the Process and Design Evaluation for the Pilot Advance Market Commitment (AMC) for Pneumococcal Vaccines. This evaluation was conducted in 2012 by Dalberg Global Development Advisors.

This report presents the findings of the Outcomes and Impact evaluation for the Pilot Advance Market Commitment (AMC) for Pneumococcal Vaccines. This evaluation was conducted in 2015 by The Boston Consulting Group.

This report presents the findings and lessons from a review of Gavi’s support to civil society organisations undertaken by Cambridge Economic Policy Associates.

Lessons learnt from the Accelerated Vaccine Introduction (AVI) Project (published 2012).

The June 2011 evaluation of the International Finance Facility for Immunisation (IFFIm) assesses whether the IFF concept is proven and whether the IFFIm pilot has worked.

The Baseline Study for the pneumococcal vaccine Advance Market Commitment establishes the environment prior to the AMC as a basis for future evaluations.

2010 review of Gavi's Independent Review Committees: their design, execution and results.

Gavi commissions 2008 report to analyse the sustainability of its Injection Safety Support.

External review of effectiveness of Gavi's ground-breaking Immunisation Services Support over its first five years (2000-2005).

The Gavi second evaluation report sets out the main findings of an independent assessment of the Vaccine Alliance's achievements in Phase II (2007-2010).

The Gavi first evaluation report sets out the main findings of an independent assessment of the Vaccine Alliance's achievements in Phase I (2000-2005).

2007 evaluation of Gavi's efforts to introduce new vaccines via the Accelerated Development and Introduction Plans and the Hib Initiative.